Correspondence 0001213900-24-078894 from Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: Sept. 16, 2024 · CIK: 0001601936 · Accession: 0001213900-24-078894
AI Filing Summary & Sentiment
File numbers found in text: 333-281724
Letter
Altamira Therapeutics Ltd.
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
September 16, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
Re: Altamira Therapeutics Ltd. (the “Company”)
Registration Statement on Form F-1 (File No. 333-281724)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 5:15 p.m., Eastern Time, on September 16, 2024, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Nelson Mullins Riley & Scarborough LLP, by calling David Mannheim at (919) 329-3804 or Mike Bradshaw at (202) 689-2808.
Sincerely,
ALTAMIRA THERAPEUTICS LTD.
Show Raw Text
CORRESP
1
filename1.htm
Altamira Therapeutics Ltd.
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
September 16, 2024
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, D.C. 20549
Re: Altamira Therapeutics Ltd. (the “Company”)
Registration Statement on Form F-1 (File No. 333-281724)
Ladies and Gentlemen:
Pursuant to Rule 461 under the
Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration
Statement”) be declared effective by the Securities and Exchange Commission at 5:15 p.m., Eastern Time, on September 16, 2024, or
as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with
our counsel, Nelson Mullins Riley & Scarborough LLP, by calling David Mannheim at (919) 329-3804 or Mike Bradshaw at (202) 689-2808.
Sincerely,
ALTAMIRA THERAPEUTICS LTD.
By:
/s/ Thomas Meyer
Name:
Thomas Meyer
Title:
Chief Executive Officer